Abstract
Breast cancer is the second leading cause of cancer death among women. National cancer institute of the US estimates that one in eight women will be diagnosed with breast cancer during their lifetime. Considering the devastating effects of the disease and the alarming numbers many scientists and research groups have devoted their research to fight breast cancer. Several recommendations are to be considered as preventing measures which include living a healthy lifestyle, regular physical activity, weight control and smoking cessation. Early detection of the disease by annual and regular mammography after the age of 40 is recommended by many healthcare institutions. This would help the diagnosis of the disease at an earlier stage and the start of the treatment before it is spread to other parts of the body. Current therapy for breast cancer includes surgical ablation, radiotherapy and chemotherapy which is often associated with adverse effects and even may lead to a relapse of the disease at a later stage. In order to achieve a long-lasting anticancer response with minimal adverse effects, development of breast cancer vaccines is under investigation by many laboratories. The immune system can be stimulated by a vaccine against breast cancer. This approach has attracted a great enthusiasm in recent years. No breast cancer vaccines have been approved for clinical use today. One breast cancer vaccine (NeuVax) has now completed clinical trial phase III and a few preventive and therapeutic breast cancer vaccines are at different steps of development. We think that with the recent advancements in immunotherapy, a breast cancer vaccine is not far from reach.
Keywords: Breast cancer, immunotherapy, NeuVax, vaccines, antigenic peptides, pathology, genetics.
Graphical Abstract
[1]
Howlader NA, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975-2014. Betesda, MD: National cancer Institute 2017.
[3]
Moriya T, Kanomata N. Up-to-date pathological diagnosis for breast cancer. Rinsho Byori 2014; 62(6): 560-7.
[4]
Bodelon C, Oh H, Chatterjee N, et al. Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. Int J Cancer 2017; 140(4): 825-32.
[5]
Slyper M, Shahar A, Bar-Ziv A, et al. Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3. Cancer Res 2012; 72(21): 5613-24.
[6]
Jafari SH, Saadatpour Z, Salmaninejad A, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 2018; 233(7): 5200-13.
[7]
Plichta JK, Campbell BM, Mittendorf EA, Hwang ES. Anatomy and breast cancer staging: Is it still relevant? Surg Oncol Clin N Am 2018; 27(1): 51-67.
[8]
Li X, Oprea-Ilies GM, Krishnamurti U. New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 2017; 141(4): 490-8.
[9]
Hamilton DH, Roselli M, Ferroni P, et al. Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. Endocr Relat Cancer 2016; 23(10): 783-96.
[10]
Sayegh HE, Asdourian MS, Swaroop MN, et al. Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: Past, present, and future directions. Curr Breast Cancer Rep 2017; 9(2): 111-21.
[11]
Corsini C, Henouda S, Nejima DB, et al. Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women. Breast Cancer Res Treat 2017; 166(2): 631-9.
[12]
Engin A. Obesity-associated Breast Cancer: Analysis of risk factors. Adv Exp Med Biol 2017; 960: 571-606.
[13]
Kullberg C, Selander J, Albin M, Borgquist S, Manjer J, Gustavsson P. Female white-collar workers remain at higher risk of breast cancer after adjustments for individual risk factors related to reproduction and lifestyle. Occup Environ Med 2017; 74(9): 652-8.
[14]
Costa M, Saldanha P. Risk reduction strategies in breast cancer prevention. Eur J Breast Health 2017; 13(3): 103-12.
[15]
Jameera Begam A, Jubie S, Nanjan MJ. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem 2017; 71: 257-74.
[16]
Xiong R, Zhao J, Gutgesell LM, et al. Novel Selective Estrogen Receptor Downregulators (SERDs) developed against treatment-resistant breast cancer. J Med Chem 2017; 60(4): 1325-42.
[17]
Yu S, Liu Q, Han X, et al. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol 2017; 6: 31.
[18]
Mittendorf EA, Peoples GE. Injecting Hope--A review of breast cancer vaccines. Oncology (Williston Park) 2016; 30(5): 475-81.
[19]
Nomura T, Hirata K, Shimaoka T, et al. Cancer vaccine therapy using tumor endothelial cells as antigens suppresses solid tumor growth and metastasis. Biol Pharm Bull 2017; 40(10): 1661-8.
[20]
Berzofsky JA, Terabe M, Trepel JB, et al. Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunol Immunother 2017.
[http://dx.doi.org/10.1007/s00262-017-2084-x]
[http://dx.doi.org/10.1007/s00262-017-2084-x]
[21]
Barati N, Razazan A, Nicastro J, et al. Immunogenicity and antitumor activity of the superlytic lambdaF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Lett 2018; 424: 109-16.
[22]
Arab A, Behravan J, Razazan A, et al. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. J Drug Target 2018; 26(4): 365-72.
[23]
Barati N, Nikpoor AR, Razazan A, et al. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunol Lett 2017; 190: 108-17.
[24]
Razazan A, Behravan J, Arab A, et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS One 2017; 12(10)e0185099
[25]
Arab A, Nicastro J, Slavcev R, et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8(+) T response. Immunol Res 2018; 66(1): 200-6.
[26]
Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: What are we missing? Clin Cancer Res 2017; 23(11): 2640-6.
[27]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
[28]
Alamolhodaei NS, Behravan J, Mosaffa F, Karimi G. MiR 221/222 as New Players in Tamoxifen Resistance. Curr Pharm Des 2016; 22(46): 6946-55.
[29]
Ghandadi M, Behravan J, Abnous K, Mosaffa F. Reactive oxygen species mediate TNF-x237A; Cytotoxic effects in the multidrug-resistant breast cancer cell line MCF-7/MX. Oncol Res Treat 2016; 39(1-2): 54-9.
[30]
Kalalinia F, Elahian F, Behravan J. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol 2011; 137(2): 321-30.
[31]
Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem 2012; 363(1-2): 385-93.
[32]
Mosaffa F, Kalalinia F, Parhiz BH, Behravan J. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2-overexpressing resistant breast cancer cells compared with their drug-sensitive parental line. DNA Cell Biol 2011; 30(6): 413-8.
[33]
Mosaffa F, Lage H, Afshari JT, Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res 2009; 58(10): 669-76.
[34]
Kasaian J, Mosaffa F, Behravan J, Masullo M, Piacente S, Iranshahi M. Modulation of multidrug resistance protein 2 efflux in the cisplatin resistance human ovarian carcinoma cells A2780/RCIS by sesquiterpene coumarins. Phytother Res 2016; 30(1): 84-9.
[35]
Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J. Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines. Planta Med 2011; 77(14): 1590-3.
[36]
Suman S, Sharma PK, Rai G, et al. Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer. Biochem Biophys Res Commun 2016; 472(3): 401-9.
[37]
Schneble E, Jinga DC, Peoples G. Breast Cancer immunotherapy. Maedica (Buchar) 2015; 10(2): 185-91.
[38]
Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: Current status and future perspectives. Ann Oncol 2013; 24(7): 1740-8.
[39]
Untch M, Ditsch N, Hermelink K. Immunotherapy: New options in breast cancer treatment. Expert Rev Anticancer Ther 2003; 3(3): 403-8.
[40]
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-72.
[41]
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-84.
[42]
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016; 14: 73.
[43]
Setiady YY, Coccia JA, Park PU. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur J Immunol 2010; 40(3): 780-6.
[44]
Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5): 430-9.
[45]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-64.
[46]
Hodi FS, O’Day SJ, McDermott DF, Weber RW, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
[47]
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-26.
[48]
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-65.
[49]
Marin M, Patel M, Oberste S, Pallansch MA. Guidance for Assessment of poliovirus vaccination status and vaccination of children who have received poliovirus vaccine outside the United States. MMWR Morb Mortal Wkly Rep 2017; 66(1): 23-5.
[50]
Deblina Datta S, Tangermann RH, Reef S, William Schluter W, Adams A. National, regional and global certification bodies for polio eradication: A framework for verifying measles elimination. J Infect Dis 2017; 216(suppl_1): S351-S4.
[51]
Nandi A, Barter DM, Prinja S, John TJ. The Estimated health and economic benefits of three decades of polio elimination efforts in India. Indian Pediatr 2016; 53(Suppl. 1): S7-S13.
[52]
Upfill-Brown AM, Voorman A, Chabot-Couture G, Shuaib F, Lyons HM. Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria. BMC Med 2016; 14: 60.
[53]
Nasir UN, Bandyopadhyay AS, Montagnani F, et al. Polio elimination in Nigeria: A review. Hum Vaccin Immunother 2016; 12(3): 658-63.
[54]
Wilson N, Baker MG. Celebrating 50 years of polio elimination in New Zealand: but inadequate progress in eliminating other vaccine-preventable diseases. N Z Med J 2012; 125(1365): 67-74.
[55]
Kumai T, Fan A, Harabuchi Y, Celis E. Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr Opin Immunol 2017; 47: 57-63.
[56]
Bilusic M, Madan RA. Therapeutic cancer vaccines: The latest advancement in targeted therapy. Am J Ther 2012; 19(6): e172-81.
[57]
Svensson S, Abrahamsson A, Rodriguez GV, et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin Cancer Res 2015; 21(16): 3794-805.
[58]
Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72(5): 1081-91.
[59]
Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19(6): 747-52.
[60]
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230): 124-8.
[61]
Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24(5): 743-50.
[62]
Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast 2016; 29: 241-50.
[63]
Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J 2016; 283(14): 2731-48.
[64]
Desjardins A, Vlahovic G, Friedman HS. Vaccine Therapy, Oncolytic Viruses, and Gliomas. Oncology (Williston Park) 2016; 30(3): 211-8.
[65]
Nourbakhsh M, Jaafari MR, Lage H, et al. Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 2015; 18(4): 385-92.
[66]
van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 2006; 24(19): 4188-200.
[67]
Ivarsson Y, Arnold R, McLaughlin M, et al. Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes. Proc Natl Acad Sci USA 2014; 111(7): 2542-7.
[68]
Wang J, Gao Y, Zhao F. Phage-bacteria interaction network in human oral microbiome. Environ Microbiol 2016; 18(7): 2143-58.
[69]
Tsai HJ. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine. Taiwan J Obstet Gynecol 2015; 54(2): 112-5.
[70]
Buonaguro FM, Buonaguro L. Cancer vaccines for hepatocellular carcinoma: future directions. Immunotherapy 2016; 8(4): 391-3.
[71]
Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18(1): 23-34.
[72]
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17(11): 3520-6.
[73]
Patel PH, Kockler DR. Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008; 42(1): 91-8.
[74]
Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: Current landscape, challenges, and opportunities. Clin Transl Sci 2016; 9(2): 89-104.
[75]
Ott PA, Hodi FS. Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res 2016; 22(13): 3127-31.
[76]
Kohlhapp FJ, Zloza A, Kaufman HL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc) 2015; 51(9): 549-58.
[77]
Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016; 8(3): 315-30.
[78]
Hammerich L, Binder A, Brody JD. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 2015; 9(10): 1966-81.
[79]
Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical development of the E75 vaccine in breast cancer. Breast Care (Basel) 2016; 11(2): 116-21.
[80]
Mittendorf EA, Ardavanis A, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget 2016; 7(40): 66192-201.
[81]
Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncol 2016; 12(11): 1321-9.
[82]
Mocellin S. Priming anticancer active specific immunotherapy with dendritic cells. Curr Opin Investig Drugs 2005; 6(6): 576-81.
[83]
Tian Y, Li M, Yu C, et al. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget 2017; 8(28): 45951-64.
[84]
Rosenthal KS, Stone S, Koski G, Zimmerman DH. LEAPS vaccine incorporating HER-2/neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model. J Immunol Res 2017; 20173613505
[85]
Gall VA, Philips AV, Qiao N, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res 2017; 77(19): 5374-83.
[86]
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66(1): 31-42.
[87]
DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67(6): 439-48.
[88]
Dubey AK, Gupta U, Jain S. Breast cancer statistics and prediction methodology: a systematic review and analysis. Asian Pac J Cancer Prev 2015; 16(10): 4237-45.
[89]
Mansour M, Teo ZL, Luen SJ, Loi S. Advancing immunotherapy in metastatic breast cancer. Curr Treat Options Oncol 2017; 18(6): 35.
[90]
Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer 2017; 3: 8.
[91]
Bertucci F, Goncalves A. Immunotherapy in breast cancer: The emerging role of PD-1 and PD-L1. Curr Oncol Rep 2017; 19(10): 64.
[92]
Chidambaram R, Terunuma H, Balamurugan M, et al. Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report. Mol Clin Oncol 2017; 7(3): 493-7.
[93]
Hickman ES, Lomax ME, Jakobsen BK. Antigen selection for enhanced affinity t-cell receptor-based cancer therapies. J Biomol Screen 2016; 21(8): 769-85.
[94]
Geldmacher A, Freier A, Losch FO, Walden P. Therapeutic vaccination for cancer immunotherapy: Antigen selection and clinical responses. Hum Vaccin 2011; 7(Suppl.): 115-9.
[95]
Haque A, Blum JS. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J Biol Regul Homeost Agents 2005; 19(3-4): 93-104.
[96]
Muntasell A, Cabo M, Servitja S, et al. Interplay between natural killer cells and anti-HER2 antibodies: Perspectives for breast cancer immunotherapy. Front Immunol 2017; 8: 1544.
[98]
Gerratana L, Bonotto M, Bozza C, et al. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opin Biol Ther 2017; 17(3): 365-74.
[99]
Gleeson JP, Keegan NM, Morris PG. Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer. Expert Opin Biol Ther 2017; 1-12.
[100]
Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002; 8(11): 3407-18.
[101]
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342(6165): 1432-3.
[102]
Dizon DS, Krilov L, Cohen E, et al. clinical cancer advances 2016: Annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2016; 34(9): 987-1011.
[103]
Polk A, Svane IM, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer - Current status. Cancer Treat Rev 2017; 63: 122-34.
[104]
Liu L, Wang Y, Miao L, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther 2018; 26(1): 45-55.
[105]
Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist Updat 2017; 32: 1-15.
Article Metrics
60
7